Aventis Rabies Ad Cited By FDA For Lack Of Risk Information
This article was originally published in The Pink Sheet Daily
Executive Summary
A poster for Imovax and Imogam should be discontinued because it does not mention adverse events, CBER says. The ad also implies that other products are not available, the agency’s letter states.
You may also be interested in...
Aventis Typhoid Promotion Cited For Effectiveness Claim
A Typhim Vi flashcard suggests the vaccine protects against typhoid without the need for reimmunization, an FDA letter states. The agency also objects to a comparative claim with another typhoid vaccine.
Aventis Typhoid Promotion Cited For Effectiveness Claim
A Typhim Vi flashcard suggests the vaccine protects against typhoid without the need for reimmunization, an FDA letter states. The agency also objects to a comparative claim with another typhoid vaccine.
Aventis Recalls Rabies Vaccine
Aventis Pasteur is recalling four lots of its rabies vaccine Imovax following discovery of a non-inactivated virus.